Back
ESC2025 Premium Access

Colchicine for the secondary prevention of cardiovascular diseases: a cumulative-dose meta-analysis of randomized controlled trials including 31,397 subjects worldwide

Session: Pharmacotherapy in acute coronary syndromes (3)
Topic: Pharmacotherapy
Speaker: Assistant Professor Y. Chan (Hong Kong, HK)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Assistant Professor Yap-Hang Will Chan

The University of Hong Kong, Hong Kong (Hong Kong)
1 presentation
1 follower

6 more presentations in this session

Comparative effectiveness of prasugrel and ticagrelor among patients undergoing contemporary PCI: insights from the BMC2 registry

Speaker: Doctor E. Dayoub (Ann Arbor, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Effect of early initiation of evolocumab on lipid profiles changes in patients with ACS Undergoing PCI (C-STAR)

Speaker: Associate Professor Y. Kim (Yongin, KR)

Access
Abstract
Slides
Video
Like
Thumbnail

Early TNF-alpha levels suppression by upstream evolocumab use in patients with acute myocardial infarction undergoing percutaneous coronary intervention

Speaker: Doctor A. Marengo (Novara, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a paradigm shift in antithrombotic strategy?

Speaker: Doctor F. Veneziano (Rome, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

A very short duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

Speaker: Doctor J. Sakaleros (Bloomington, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Pharmacotherapy in acute coronary syndromes (3)

Speakers: Assistant Professor Y. Chan, Doctor E. Dayoub, Associate Professor Y. Kim, Doctor A. Marengo, Doctor F. Veneziano...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources